ERBB2 and breast cancer: In breast cancer, extracranial disease is present in ~80% of patients with BM [10,11], but in contrast to earlier RTOG studies, recent meta-analyses found that extracranial disease is not prognostic after accounting for human epidermal growth factor receptor 2 (HER2) and hormone receptor status [3].